Roivant Sciences Acquires Experimental Pulmonary Hypertension Drug Mosliciguat from Bayer

Acquisition:
Roivant Sciences has acquired the experimental pulmonary hypertension drug mosliciguat from Bayer under an in-license agreement worth up to $294 million.

Drug Details:
Mosliciguat is a potential first-in-class inhaled soluble guanylate cyclase (sGC) activator being developed for pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Clinical Data:
Phase 1b ATMOS study results showed that mosliciguat led to sustained, clinically meaningful reductions in pulmonary vascular resistance (PVR) of up to 38%, with once-daily dosing via a dry powder inhaler being generally well-tolerated.

Development Plan:
Pulmovant, a new subsidiary of Roivant Sciences, will advance mosliciguat through Phase II development with the PHocus study, expected to begin imminently and enroll approximately 120 patients with PH-ILD.

Market Opportunity:
PH-ILD affects an estimated 200,000 patients in the U.S. and Europe, with limited treatment options, representing a significant commercial opportunity.

Agreement Terms:
Bayer received an upfront payment of $14 million and could receive up to $280 million in future development, regulatory, and commercial milestones, plus tiered royalties on sales.